Unicycive Therapeutics Completes The UNI-494 Phase 1 Study In Healthy Volunteers, These Results Will Help Determine The Dose And Schedule Of UNI-494 For A Potential Phase 2 Trial In Patients With Acute Kidney Injury
Unicycive Therapeutics Completes The UNI-494 Phase 1 Study In Healthy Volunteers, These Results Will Help Determine The Dose And Schedule Of UNI-494 For A Potential Phase 2 Trial In Patients With Acute Kidney Injury
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.